The updated efficacy rate results from 34 study participants, according to Pfizer.
Four infant cases showed a vaccine efficacy rate of 75.8 percent and nine cases among children aged between 2 and 4 found a 71.8 percent efficacy rate.
The FDA and CDC initiated emergency use authorization for Pfizer’s vaccine for the youngest population June 17, and Moderna’s vaccine for children 6 months to 5 years old was authorized the same day. Pfizer’s data at that time — before omicron subvariants BA.4 and BA.5 surged — showed an 80 percent efficacy rate. Moderna reported a 50.6 percent efficacy rate for infants 6 to 23 months old and a 36.8 percent efficacy rate for 2- to 5-year-olds.
As omicron subvariant BA.5 accounts for a high proportion of national cases, Pfizer is steaming ahead to gain federal approval of its tweaked vaccine booster aimed at BA.5.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
